HU Group Holdings Inc. and its subsidiary Fujirebio announced the availability of Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for fully automated random access LUMIPULSE® G immunoassay systems. These Chemiluminescent Enzyme Immunoassay (CLEIA) assays allow the quantitative measurement of neurofilament lumen (NfL) in human cerebrospinal fluid (CSF) and human plasma/serum, respectively, in just 35 minutes. Both tests are available for research only. The new biomarker tests will allow researchers and clinical research professionals around the world to further investigate the clinical utility of NfL in various pathologies such as multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s or Alzheimer’s disease, as well as in acute situations such as traumatic brain injury.
NfL is considered a promising biomarker for disease activity, disease progression, prognosis, and monitoring therapy efficacy. Lab professionals can select their preferred sample matrix and measure NfL on the fully automated, random-access LUMIPULSE G platform. This family of standardized immunoassay systems is widely available and used in routine laboratories active in neurological disease with its current menu of assays.
The LUMIPULSE G platform meets the necessary throughput, quality and regulatory requirements to enable potential routine use of NfL in addition to the existing portfolio.
